Xilio Therapeutics (XLO) Total Current Liabilities (2020 - 2026)

Xilio Therapeutics has reported Total Current Liabilities for 7 years, with the latest figure at $43.0 million in Q1 2026.

• Quarterly Total Current Liabilities fell 9.82% year-over-year to $43.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $43.0 million (down 9.82% YoY) and the FY2025 annual result came in at $56.3 million, up 106.42% from the prior year.
• Total Current Liabilities declined to $43.0 million in Q1 2026 per XLO's latest filing, from $56.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $56.4 million in Q3 2025 and troughed at $12.2 million in Q1 2022.
• A 5-year average of $30.9 million and a median of $27.3 million in 2024 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities dropped 24.44% in 2023, then soared 137.16% in 2024.
• Over 5 years, Total Current Liabilities stood at $21.1 million in 2022, then decreased by 24.44% to $16.0 million in 2023, then jumped by 70.84% to $27.3 million in 2024, then soared by 106.42% to $56.3 million in 2025, then retreated by 23.66% to $43.0 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $43.0 million, $56.3 million, and $56.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.